357 related articles for article (PubMed ID: 29495928)
1. Nanomedicine: is it lost in translation?
Greish K; Mathur A; Bakhiet M; Taurin S
Ther Deliv; 2018 Mar; 9(4):269-285. PubMed ID: 29495928
[TBL] [Abstract][Full Text] [Related]
2. Smart cancer nanomedicine.
van der Meel R; Sulheim E; Shi Y; Kiessling F; Mulder WJM; Lammers T
Nat Nanotechnol; 2019 Nov; 14(11):1007-1017. PubMed ID: 31695150
[TBL] [Abstract][Full Text] [Related]
3. Nanomedicine therapeutic approaches to overcome cancer drug resistance.
Markman JL; Rekechenetskiy A; Holler E; Ljubimova JY
Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1866-79. PubMed ID: 24120656
[TBL] [Abstract][Full Text] [Related]
4. Polymer therapeutics at a crossroads? Finding the path for improved translation in the twenty-first century.
Duncan R
J Drug Target; 2017; 25(9-10):759-780. PubMed ID: 28783978
[TBL] [Abstract][Full Text] [Related]
5. Emerging therapeutic nanotechnologies in pancreatic cancer: advances, risks and challenges.
Rebelo A; Reis C
Ther Deliv; 2018 Oct; 9(10):691-694. PubMed ID: 30277137
[No Abstract] [Full Text] [Related]
6. Targeting cancer with hyaluronic acid-based nanocarriers: recent advances and translational perspectives.
Cadete A; Alonso MJ
Nanomedicine (Lond); 2016 Sep; 11(17):2341-57. PubMed ID: 27526874
[TBL] [Abstract][Full Text] [Related]
7. Nanomedicine: the promise and challenges in cancer chemotherapy.
Naguib YW; Cui Z
Adv Exp Med Biol; 2014; 811():207-33. PubMed ID: 24683034
[No Abstract] [Full Text] [Related]
8. Role of integrated cancer nanomedicine in overcoming drug resistance.
Iyer AK; Singh A; Ganta S; Amiji MM
Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1784-802. PubMed ID: 23880506
[TBL] [Abstract][Full Text] [Related]
9. Issues affecting nanomedicines on the way from the bench to the market.
Longo JPF; Mussi S; Azevedo RB; Muehlmann LA
J Mater Chem B; 2020 Dec; 8(47):10681-10685. PubMed ID: 33155000
[TBL] [Abstract][Full Text] [Related]
10. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
Pérez-Herrero E; Fernández-Medarde A
Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
[TBL] [Abstract][Full Text] [Related]
11. Above and Beyond Cancer Therapy: Translating Biomaterials into the Clinic.
Conde J
Trends Cancer; 2020 Sep; 6(9):730-732. PubMed ID: 32430152
[TBL] [Abstract][Full Text] [Related]
12. Translational considerations in nanomedicine: The oncology perspective.
Gabizon AA; de Rosales RTM; La-Beck NM
Adv Drug Deliv Rev; 2020; 158():140-157. PubMed ID: 32526450
[TBL] [Abstract][Full Text] [Related]
13. Grand challenges in nanomedicine.
Wu LP; Wang D; Li Z
Mater Sci Eng C Mater Biol Appl; 2020 Jan; 106():110302. PubMed ID: 31753337
[TBL] [Abstract][Full Text] [Related]
14. To exploit the tumor microenvironment: Since the EPR effect fails in the clinic, what is the future of nanomedicine?
Danhier F
J Control Release; 2016 Dec; 244(Pt A):108-121. PubMed ID: 27871992
[TBL] [Abstract][Full Text] [Related]
15. Research progress of novel inorganic nanometre materials carriers in nanomedicine for cancer diagnosis and treatment.
Xu J; Liao K; Jiang H; Zhou W
Artif Cells Nanomed Biotechnol; 2018; 46(sup3):S492-S502. PubMed ID: 30449177
[TBL] [Abstract][Full Text] [Related]
16. Advances in stimuli responsive nanobiomaterials for cancer therapy.
Sampathkumar K; Arulkumar S; Ramalingam M
J Biomed Nanotechnol; 2014 Mar; 10(3):367-82. PubMed ID: 24730233
[TBL] [Abstract][Full Text] [Related]
17. Soft matter assemblies as nanomedicine platforms for cancer chemotherapy: a journey from market products towards novel approaches.
Jäger E; Giacomelli FC
Curr Top Med Chem; 2015; 15(4):328-44. PubMed ID: 25633209
[TBL] [Abstract][Full Text] [Related]
18. New strategies in melanoma therapy: can nanoparticles overcome chemoresistance?
Badea I
Nanomedicine (Lond); 2017 Jul; 12(14):1623-1626. PubMed ID: 28635551
[No Abstract] [Full Text] [Related]
19. Improved Targeting of Cancers with Nanotherapeutics.
Foster C; Watson A; Kaplinsky J; Kamaly N
Methods Mol Biol; 2017; 1530():13-37. PubMed ID: 28150194
[TBL] [Abstract][Full Text] [Related]
20. Nanotechnology platforms and physiological challenges for cancer therapeutics.
Kim KY
Nanomedicine; 2007 Jun; 3(2):103-10. PubMed ID: 17442621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
